

Mayne Pharma Group Limited (ACN 115 832 963)
Half Year Results Presentation 2011

25 February 2011

Highlights of the last six months

- EU registration filed for SUBACAP®
- Successful US-based Phase II trial for SUBACAP®
- Change of company name to Mayne Pharma Group Limited
- New Chairman and CFO appointed
- Maiden dividend paid and special dividend declared
- New Doryx® formulations

Executive Summary

- Strengthened A$ and a delay in the approval of new Doryx® formulations has resulted in earnings not meeting Company expectations for the half
- Australian proprietary products division sales were up following acquisition of the marketing and distribution rights from Hospira in February 2010
- US$10M debt reduced to US$3.75M at end of January
- Special fully franked dividend of 1.0cps
- Continued legal action to protect Doryx® patent
- Seeking regulatory approval in EU for SUBACAP® in 2011 and clarity around US clinical development path from the FDA in the 2nd quarter of calendar 2011

Consolidated results for the half-year ended 31/12/10

- Total revenue $26.9m
- Gross profit $12.2m
- EBITDA $5.1m
- EBITDA margin 18.9%
- NPAT $1.1m
- EPS 0.76cps
- Net operating cash flow before tax of $3.7m
- Cash on hand $13.4m
- Net cash (cash less debt) of $8.5m
- Special dividend declared 1.0cps

H11 Earnings comparison

$ millions	H11 Reported	H10 Reported	Last 12 months
Total revenue	**26.9**	**9.3**	**54.3**
Gross profit	12.2	5.2	24.6
EBITDA	**5.1**	**(0.4)**	**14.0**
Depreciation	(0.9)	(0.3)	(1.9)
EBITA	**4.2**	**(0.7)**	**12.1**
Amortisation	(3.1)	0.0	(8.6)
EBIT	**1.1**	**(0.7)**	**3.5**
Net interest	(0.8)	(0.4)	
Tax	0.8	(1.1)	
NPAT	**1.1**	**(2.2)**	
EPS (cents per share)	0.8	(2.1)	
EBITDA margin	18.9%	(4.4%)	25.8%

Key features of the results

- Stronger AUD resulted in a net loss from foreign exchange of $0.8m for the half
- $1.7m margin shortfall from the agreed delay in Warner Chilcott orders for Doryx® tablets
- Notional interest charge of $0.9m for the earn-out liability
- Savings in outward distribution costs and trading expenses against budget ($0.4m or 22%)
- EU replicate study for SUBACAP® of $0.6m to support commercialisation of the drug ($1.1m in F11)

Balance Sheet Position

$ millions	H11	F10	H10	Change
Cash	13.4	19.7	14.6	(32.0%)
Inventory & receivables	14.0	12.5	11.3	11.8%
PP&E	21.3	21.0	19.3	1.3%
Intangibles	11.2	14.2	13.3	(21.0%)
Other	3.9	3.8	2.1	3.6%
Total assets	63.8	71.2	60.6	(10.4%)
Interest bearing debt	4.9	8.6	10.9	(43.3%)
Earn out liability	21.8	21.0	21.6	3.9%
Total liabilities	39.3	45.6	41.3	(13.8%)
Equity	24.5	25.5	19.4	(4.0%)
Net debt (debt less cash)	(8.5)	(11.1)	(3.7)	(23.2%)
Debt / Debt + Equity	16.6%	25.2%	36.0%	

Key features of the Balance Sheet movements

- Cash reduction due to the payment of the maiden dividend ($3.0m), reduction in the US$ NAB loan ($2.7m) and tax payments ($2.9m)
- Increase in receivables from June due largely to the timing of a payment by Warner Chilcott (received in January 2011)
- Reduction in intangibles reflects aggressive amortisation schedule as foreshadowed at the end of FY10
- Debt reduced to less than half of the 31 December 2009 level
- Earn-out liability increased due to the notional (non-cash) interest charge reflecting the unwind of the discount ($0.9m)

Cash flow

$ millions	H11
EBIT - reported	**1.1**
Amortisation / depreciation	4.0
Change in working capital	(1.4)
Net interest paid	(0.0)
Tax paid	(2.9)
Net operating cash flow	**0.8**
Capex	(1.1)
Acquisitions	0.0
Repayment of borrowings	(2.7)
Net proceeds from issue of shares	0.8
Dividends paid	(3.0)
Net cash flow	**(5.2)**
FX impact on cash	(1.1)
Cash on hand at 30 June 2010	**19.7**
Cash on hand at 31 December 2011	**13.4**

Doryx®

- Doryx® our key proprietary product representing ~50% of revenue
- Doryx® revenue impacted by
  - the stronger than expected AUD:
    forecast rate AUD/USD: 90c vs
    average actual settled rate of AUD/USD: 94c
  - delay in FDA approval of new formulations led to agreed deferral of orders with Warner Chilcott
- Vigorously defending patent which underpins marketing exclusivity for Doryx® in the US

Astrix®

- Astrix® number 1 prescribed low dose aspirin in Australia representing 17% of group sales
- Astrix® sales and margins increased following acquisition of marketing and distribution rights from Hospira
- New consumer focused website www.astrixaspirin.com.au launched
- Partnership with HealthOne to promote Astrix® brand of products in pharmacies in Australia

SUBACAP®

- Super-bioavailable Itraconazole
- Patent protected
- EU registration filed Dec 2010
- Successful US based Phase II trial results in Nov 2010
- EU approval expected by end calendar 2011
- FDA meeting in 2nd quarter 2011 to discuss trial results and determine US regulatory path
- Reviewing potential licensing partners around the world

Anti Fungal Global Market (US$m)



Total Value US$4.87 billion
Itraconazole US$545 million

Source: Thomson Reuters June 2010

Clinical Development Path - SUBACAP®



Outlook

- The Company is in the process of transitioning into new improved Doryx® formulations
  - In view of the regulatory uncertainty surrounding FDA approval and the strategic decision to allow our major partner Warner Chilcott to delay orders, the previous guidance of EBITDA not less than $18.2M is no longer appropriate
  - Normalisation of Doryx® supply is expected once FDA approval granted
  - The longer term position may improve given the possibility of price increases being implemented
- The Directors remain confident in the resilience and sustainability of our business model with our strong product portfolio and pipeline, particularly given the recent filing of SUBACAP® for registration in EU and ongoing discussions with potential marketing and distribution partners

Dividend & debt repayment

- After careful consideration of the outlook for the Company, the Board of Mayne Pharma has declared a special fully franked dividend of 1.0cps
  - Record date: 9th March 2011
  - Payable: 25th March 2011
- US$ debt to be completely paid down in 2011

H11 Milestones

Achieved

- ✓ SUBACAP® dossier lodged
- ✓ Successful Phase II trial of SUBACAP® in US
- ✓ Settlement with Heritage
- ✓ Special dividend

Ongoing

- Appointment of marketing and distribution partner for SUBACAP®
- Regulatory approval of SUBACAP® in EU and US
- Clarity around Doryx® lifecycle management
- Resolution of Doryx® patent litigation
- In licence/acquire/develop new products

Definitions and glossary of terms

- IND – Investigational New Drug Application
- IMPD – Investigational Medical Product Dossier
- MHRA – Medicines and Healthcare Products Regulatory Agency (UK)
- Pharmacokinetic study are performed to examine the absorption, distribution, metabolism and excretion of a drug under investigation in healthy volunteers
- Clinical studies are conducted in patients to determine safety and efficacy